The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies: Trends in Cancer
Cells | Free Full-Text | Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Molecules | Free Full-Text | Development of CDK4/6 Inhibitors: A Five Years Update
Medicinrådets vurdering vedr. alpelisib i komb. med fulvestrant til metastatisk brystkræft-vers 1.0
Ribociclib
Ribociclib
CDK 4/6-hæmmer plus førstelinjebehandling forlænger overlevelsen ved metastaserende brystkræft - Dagens Medicin
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Potential combination strategies for CDK4/6 inhibitors. CDK4/6... | Download Scientific Diagram
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
Frontiers | CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences | SpringerLink
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization | Journal of Experimental & Clinical Cancer Research | Full Text
Frontiers | CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Cancers | Free Full-Text | Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
The Biological Rationale for CDK4/6 Inhibitors - YouTube
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer - ScienceDirect
ASCO 2016 - Brystkræft
Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies | Acta Pharmacologica Sinica
CDK4/6 inhibition in breast cancer: current practice and future directions. - Abstract - Europe PMC
The application and prospect of CDK4/6 inhibitors in malignant solid tumors | Journal of Hematology & Oncology | Full Text
